Crescent Biopharma Inc.
CBIO | NASDAQ
$13.51
+$0.03 (+0.22%)
Nov 2, 2026, 9:48 AM ET · Market open
Market Data
Market Cap $501.81M
Enterprise Value $332.4M
Beta 1.26
Average Volume 387.91K
Shares Outstanding (Diluted) 30.53M
Shares Change YoY 691.62%
Institutional Ownership 95.52%
Exchange NASDAQ
ISIN KYG2545C1042
Price Performance
Price Change 1M -5.7%
Price Change 3M -9.2%
Price Change 6M -24.6%
Price Change YTD 13.9%
Price Change 1Y 9.4%
Price Change 3Y -90.0%
Price Change 5Y -93.4%
1M CAGR (ann.) -20.2%
1Y CAGR (ann.) 7.8%
5Y CAGR (ann.) -41.5%
All-Time CAGR -31.6%
Valuation
PE Ratio -1.78
Forward PE N/A
PEG Ratio -0.01
Forward PEG 0.03
PS Ratio 42.29
Forward PS 105.00
PB Ratio 3.08
P/FCF Ratio -3.27
P/Adj. FCF Ratio -2.98
P/OCF Ratio -5.68
EV/Sales 27.97
EV/EBIT -2.04
EV/EBITDA -2.04
EV/FCF -2.16
Earnings Yield -56.0%
FCF Yield -30.6%
Adj. FCF Yield -33.5%
Financial Health
Net Cash $171.59M
Total Debt $1.44M
Cash & Short-Term Investments $171.59M
Total Assets $182.76M
Current Ratio 9.66
Quick Ratio 9.66
Debt / Equity Ratio 0.01
Debt / EBITDA -0.01
Debt / FCF -0.01
OCF / Debt -50.58
Interest Coverage 0.00
Altman Z-Score 11.89
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 100.0%
Operating Profit Margin -1417.7%
EBITDA Margin -1371.0%
Net Profit Margin -1371.5%
FCF Margin -1292.8%
Adj. FCF Margin -1417.4%
SBC / Revenue 124.6%
SBC Impact (per share) -9.6%
Returns
Return on Assets -89.2%
Return on Equity -97.8%
Return on Invested Capital -102.3%
Return on Capital Employed -102.6%
Return on Tangible Assets -89.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 149.8%
Revenue CAGR 5Y 39.9%
Revenue CAGR 10Y 78.9%
EPS CAGR 3Y 58.4%
EPS CAGR 5Y 34.6%
EPS CAGR 10Y 12.5%
FCF CAGR 3Y -77.4%
FCF CAGR 5Y -29.6%
FCF CAGR 10Y -12.1%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 2
EPS Growth Next 3Y 18.8%
Revenue Growth Next 3Y 12.1%
Earnings Date Nov 5, 2026
EPS Estimate (next Q) -$0.67
EPS Growth Est (next Q) -46.9%
Revenue Est (next Q) $357.14K
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $36.00
Price Target Upside 166.1%
Cash Flow
Operating Cash Flow $-72.68M
Free Cash Flow $-153.62M
Adj. Free Cash Flow $-168.43M
FCF Per Share -$5.03
OCF Per Share -$2.38
OCF/S Ratio -611.6%
Income Statement
Revenue $11.88M
Gross Profit $11.88M
Operating Income $-168.47M
EBITDA $-162.91M
Net Income $-162.98M
EPS (Diluted) -$7.58
Revenue / Employee $270.07K
Profit / Employee $-3.7M
Employees 44
Add to Watchlist
Select watchlists to add or remove CBIO